May 05, 2011, 05.43 PM | Source: Moneycontrol.com
Strides Arcolab Thursday said it has got approval from US Food and Drug Adminstrator for its general anesthetic injection, Midazolam in multiple-dose vials.
The pharmaceutical company has got approval to market Midazolam injection of 1 mg/ml packaged in 10mg/10 ml multiple-dose vials and 5mg/ml packages in 25 mg/5ml and 50 mg/10ml multiple-dose vials.
Midazolam Injection will be launched in the third quarter of 2011-12, in partnership with US-based Sagent Pharmaceuticals and aims to address over 95% of the sterile injectable market for Midazolam in the US.
The total market for Midazolam in the USA is about USD 51 million, according to IMS September 2010 data, the company said in a press release to the stock exchanges.
At 13:50 hrs, shares of Strides Arcolab was trading at Rs 389.35, down 1% on the Bombay Stock Exchange.
Strides Shasun stock price
On May 27, 2016, Strides Shasun closed at Rs 1119.75, up Rs 10.30, or 0.93 percent. The 52-week high of the share was Rs 1412.45 and the 52-week low was Rs 848.00.
The company's trailing 12-month (TTM) EPS was at Rs 19.43 per share as per the quarter ended March 2016. The stock's price-to-earnings (P/E) ratio was 57.63. The latest book value of the company is Rs 168.32 per share. At current value, the price-to-book value of the company is 6.65.
The company has received approval from the US Food
Strides Shasun has received approval from the Unit
Ashwani Gujral of ashwanigujral.com recommends buy
The company has received tentative approval from t
The product will be manufactured at company's oral
Strides Shasun has received tentative approval fro
HeidelbergCement India has reported a sales turnov
Medi-Caps has reported a sales turnover of Rs 6.77